Add to Favorites Newsroom RSS Share
fb-shareUniversity of Texas M. D. Anderson Cancer Center
Houston, TX USA

Our News on Newswise

Newswise: DePinho.jpeg

MD Anderson study confirms protein as potential cause of most common type of pancreatic cancer

An oncogene, UPS21, has been confirmed as a frequently amplified gene in pancreatic ductal adenocarcinoma, the most common and often lethal form of pancreatic cancer. The discovery could lead to new treatment options.
4-Sep-2019 12:00 PM EDT Add to Favorites

MD Anderson receives $55 million over five years in comprehensive cancer center status renewal

MD Anderson's status as one of 51 comprehensive cancer centers was renewed for $55 million over five years by the National Cancer Institute.
22-Aug-2019 10:30 AM EDT Add to Favorites

Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies

Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.
12-Aug-2019 7:00 AM EDT Add to Favorites

Newswise: florencia_mcallister.jpg

Bacteria on Tumors Influences Immune Response and Survival of Patients with Pancreatic Cancer

MD Anderson researchers find tumor microbiome influences immune response and patient survival in pancreatic cancer. Study points to fecal transplant as possible treatment.
6-Aug-2019 2:15 PM EDT Add to Favorites

Newswise: EXTERIOR_view-31.jpg

MD Anderson to expand Proton Therapy Center

The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a groundbreaking ceremony. The expansion will more than double the center’s size to more than 160,000 square feet – almost the size of...
7-Aug-2019 1:05 PM EDT Add to Favorites

Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations

A Phase II clinical trial led by MD Anderson found that treatment with the FGFR inhibitor erdafitinib was effective in 40% of patients with metastatic bladder cancers marked by FGFR3 mutations. The trial results led to FDA approval of the drug.
23-Jul-2019 5:00 PM EDT Add to Favorites

Newswise: Giancotti.jpg

Discovery shows how difficult-to-treat prostate cancer evades immune system

Discovery shows how difficult-to-treat prostate cancer evades immune system and reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs.
17-Jul-2019 1:05 PM EDT Add to Favorites

Newswise: Li_Chuan_Chan.jpg

New biomarker-guided strategy has potential for liver cancer treatment

A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma, the...
15-Jul-2019 10:05 AM EDT Add to Favorites


see all news

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

see all experts

Our YouTube Videos

About

About section not configured. Is this your member page? Login to edit, or contact member@newswise.com to configure this module.

Contacts

Clayton Boldt

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Senior Communications Specialist

kburton@mdanderson.org

713-792-8034

Kelly Calagna

kccalgna@mdanderson.org

Scott Merville
Program Manager

smerville@mdanderson.org

713-792-0661

Meagan Raeke

meraeke@mdanderson.org

Allison Schaffer
Senior Communications Specialist

ASchaffer@mdanderson.org

713-745-1357

Twitter twitter-icon

Chat now!